Matt Britz, Chief Operating Officer  Oct. 11 | 4:15pm | Oxford Biomedica Ballroom  Natick, MA  (Private)  In-person Presentation  AffyImmune is realizing the potential of cancer immunotherapy by extending the anti-cancer activity of CAR T cell therapy to solid tumors. AffyImmune’s proprietary technology allows fine-tuning of the affinity of CAR T cells...

Petter Bjorquist, Ph.D., CEO  Oct. 12 | 4:00pm | Oxford Biomedica Ballroom  Gothenburg, Sweden  (Private)  In-person Presentation  VERIGRAFT is a Swedish biotechnology company run by experienced entrepreneurs and mastering a unique, breakthrough technology in the field of advanced therapies and regenerative medicine. We make transplantation possible without the severe risks of...

Richard Porter, Ph.D., Chief Business Officer  Oct. 11 | 2:15pm | UBC Ballroom  Lexington, MA  (NASDAQ: QURE)  In-person Presentation  uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe diseases.  www.uniqure.com  ...

Delara Motlagh, Ph.D., General Manager, Cell Therapy Technologies Oct. 12 | 5:15pm | Oxford Biomedica Ballroom   Lakewood, CO  (NASDAQ: TRUMF)  In-person Presentation  Cell and gene therapy developers work with Terumo Blood and Cell Technologies when they want more than just our portfolio of automated devices. Not only do we enable unparalleled...

Faraz Ali, CEO Oct. 11 | 11:45am | UBC Ballroom   San Francisco, CA  (NASDAQ: TYNA)  In-person Presentation  Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop, and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and...

Philip Toleikis, Ph.D., President and CEO Oct. 11 | 3:00pm | UBC Ballroom   Ontario, Canada  (TSXV: SVA)  In-person Presentation  Sernova is a clinical-stage biotechnology company developing regenerative therapeutic technologies to deliver a functional cure for chronic diseases, including insulin-dependent diabetes, thyroid disease, and rare diseases like Hemophilia A. An ongoing Phase I/II...

Timothy Lu, M.D., Ph.D., Co-founder and CEO Oct. 11 | 5:30pm | UBC Ballroom   San Francisco, CA  (NASDAQ: SNTI)  In-person Presentation  Senti Biosciences’ mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. To accomplish this, we are building a synthetic biology platform...

Nina Hunter, Ph.D., Vice President, Corporate Strategy  Oct. 12 | 1:45pm | UBC Ballroom  Rockville, MD  (NASDAQ: RGNX)  In-person Presentation  REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of...

Jane Lebkowski, Ph.D., President  Oct. 12 | 2:00pm | Oxford Biomedica Ballroom  Menlo Park, CA  (Private)  In-person Presentation  Regenerative Patch Technologies (RPT) is a biotechnology company focused on the development of cell-based implant technology for the treatment of retinal diseases. RPT has developed a composite subretinal implant, termed the California Project...

Cindy Atwell, Senior Vice President, Business Development Oct. 11 | 5:15pm | UBC Ballroom  Durham, NC  (NASDAQ: DTIL)  In-person Presentation   Precision BioSciences is a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform designed with...

By using this website you agree to accept our Privacy Policy and Terms & Conditions